Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Exclusion Criteria

• •Patients with current or prior invasive malignancy unless disease free for minimum of 1 year
• •Brain metastases \> 3 cm
• •Brain lesions causing midline shift or herniation \> 1 cm
• •Patients with unirradiated post-neurosurgical metastasectomy resection cavities, unless disease-free in the surgical bed for \>= 6 months, are prohibited from pilot study enrollment
• •No patients who require resection cavity radiation for treatment of a resected brain metastasis (i.e.: standard of care treatment) are eligible for enrollment
• •Receipt of chemotherapeutic agents (other than CDK4/6 inhibitors or hormone receptor-related targeted agents) within 2 weeks of planned radiosurgery date
• •Prior whole brain or craniospinal radiotherapy
• •Fractionated radiation to unrelated central nervous system (CNS) tumor
• •Concurrent malignant CNS tumor
• •Recurrent or progressive brain metastasis necessitating surgical or medical intervention (i.e.: a non-radiotherapy intervention such as steroids)
• •Recurrence or progressive brain metastasis from prior surgical resection necessitating surgical or medical intervention (i.e.: a non-radiotherapy intervention)
• •Brain stem metastasis \>= 1 cm
• •Patients with scleroderma
• •Severe acute co-morbidity, defined as follows:
• •* Unstable angina and/or congestive heart failure requiring hospitalization in the last 3 months
• •* Transmural myocardial infarction within the last 6 months
• •* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• •* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization in the last 6 months or precluding study therapy due to inability to rest supine at the time of registration